 Approximately 50 subjects will be randomised into the study including approximately 16 subjects in the sputum sub-study. Each subject will complete two treatment periods: subjects will be randomised to receive GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days - 2 days via the DISKUSTM dry powder inhaler DPI. 